Ocugen (NASDAQ:OCGN – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a report issued on Wednesday, Benzinga reports. They presently have a $7.00 price target on the stock.
Separately, Maxim Group began coverage on Ocugen in a research report on Tuesday, October 15th. They set a “buy” rating and a $4.00 target price on the stock.
View Our Latest Research Report on Ocugen
Ocugen Stock Performance
Ocugen (NASDAQ:OCGN – Get Free Report) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.02. The firm had revenue of $1.14 million for the quarter. During the same quarter last year, the firm earned ($0.10) earnings per share. As a group, analysts expect that Ocugen will post -0.2 earnings per share for the current fiscal year.
Institutional Trading of Ocugen
Several institutional investors and hedge funds have recently bought and sold shares of OCGN. Headlands Technologies LLC purchased a new stake in Ocugen during the 1st quarter valued at about $66,000. State Board of Administration of Florida Retirement System bought a new stake in Ocugen during the 1st quarter valued at about $132,000. Tidal Investments LLC bought a new position in shares of Ocugen in the first quarter worth approximately $108,000. Baader Bank Aktiengesellschaft bought a new position in Ocugen in the 2nd quarter valued at approximately $35,000. Finally, Bank of New York Mellon Corp boosted its position in shares of Ocugen by 2,760.5% during the second quarter. Bank of New York Mellon Corp now owns 751,819 shares of the company’s stock valued at $1,165,000 after buying an additional 725,536 shares during the last quarter. 10.27% of the stock is currently owned by hedge funds and other institutional investors.
Ocugen Company Profile
Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.
Recommended Stories
- Five stocks we like better than Ocugen
- How to Calculate Options Profits
- Bet on These 3 High-Yield Stocks as Natural Gas Demand Grows
- Using the MarketBeat Dividend Yield Calculator
- Gold Prices Hit Record Highs: Is It Time to Buy or Take Profits?
- Dividend Payout Ratio Calculator
- Value Stocks Gaining Momentum – Will They Beat Growth Stocks?
Receive News & Ratings for Ocugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocugen and related companies with MarketBeat.com's FREE daily email newsletter.